DvH Ventures
VC Fund
Köln, Germany
DvH Ventures is a VC fund in Köln focused on Health Care and Software. Dieter von Holtzbrinck Ventures (DvH Ventures) is one of Europe's leading early stage investors. As an entrepreneurial venture capitalist, DvH Ventures invests in emerging technology companies and builds successful investment clusters including Digital Health, Education, Industrial and Climate Tech with a focus on B2B SaaS, Deep Tech and AImodels.In addition to financial investments, DvH Ventures supports its portfolio companies with management expertise, in-depth industry knowledge and an international investor network. An exclusive media-for-equity program gives portfolio companies access to extensive media reach through leading publishing brands such as Handelsblatt, DIE ZEIT, Tagesspiegel and Apotheken Umschau.Founded in 2014, partners Duc Quyen Tran, Peter Richarz and Fabian von Trotha manage several venture capital funds from their Cologne office.
- Total investments:
- 90
- Last investment:
- Lead investor:
- 33%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries DvH Ventures invests in
Stages DvH Ventures invests in
Countries DvH Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.2M–$7.7M
- Series A
- $3.8M–$31M
Investment Focus
Industry
- Health Care 11 (12%)
- Software 10 (11%)
- Financial Services 9 (10%)
- FinTech 8 (9%)
- Finance 6 (7%)
Stage
- Seed 29 (32%)
- Series A 18 (20%)
- Funding Round 5 (6%)
- Series B 4 (4%)
- Pre-Seed 3 (3%)
Country
- Germany 33 (37%)
- Austria 2 (2%)
- United Kingdom 2 (2%)
- Switzerland 1 (1%)
- Liechtenstein 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Gabriel Grabner
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Peter Richarz
Founding Partner
|
Founding Partner | Total investments: 10 | Find email | |
Caner Uslu
Investment Analyst
|
Investment Analyst | Total investments: 0 | Find email | |
Cihat Cengiz
Principal
|
Principal | Total investments: 0 | Find email | |
Fabian Trotha
Managing Partner
|
Managing Partner | Total investments: 13 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
microsynetics GmbH
|
Developing hardware and software to help elderly people gaining more freedom and quality of life. Our first product is an emergency wristband which works together with an app, also connecting relatives via smartphone and phone integrated in the emergency wristband. The automated AI-based fall detection guarantees help even when the user - afteraccident - isn't capable anymore of activating the emergency call via integrated button. | $10M / Series A / Feb 05, 2026 | |
Dermanostic
|
Dermanostic is an e-health app where patients receive a medical diagnosis and therapy recommendation for skin diseases. | $5.9M / Seed / Jun 27, 2025 | |
a2zebra
|
a2zebra is a zebra company that specializes in instructional technology for elementary school kids. | $2.9M / Seed / Jun 18, 2025 | |
Buynomics
|
Imagine knowing your customers’ preferences without tedious analyses, complex spreadsheets, or unreliable focus groups. Buynomics’ AI transforms all your readily available data into Virtual Customers that mimic the buying decisions of real consumers with unmatched precision.Use these instant and accurate consumer insights as the single source oftruth to make decisions on prices, promotions, products, trade terms, channel & portfolio mix. Our holistic approach uncovers the links between critical revenue levers and provides fast and reliable recommendations for best results - your key to profitable and sustainable decisions. | $30M / Series B / Mar 20, 2025 | |
HelloBetter
|
HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services. | $6.5M / Venture - Series Unknown / Mar 05, 2025 | |
OneTwenty
|
OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes. | Seed / Mar 01, 2025 | |
LiveEO
|
LiveEO is a leading provider of insights-as-a-service, revolutionizing large-scale infrastructure monitoring worldwide with AI and satellite data. Services span from railway, power line, and pipeline monitoring, to supply chain risk management, delivering actionable insights on ground movement, vegetation management, and deforestation.LiveEO's innovative approach is redefining industry practices, improving operational efficiency, and safeguarding infrastructure safety and sustainability, setting new standards in asset management. | $26.8M / Series B / Jun 25, 2024 | |
|
LiveEO
|
LiveEO is a leading provider of insights-as-a-service, revolutionizing large-scale infrastructure monitoring worldwide with AI and satellite data. Services span from railway, power line, and pipeline monitoring, to supply chain risk management, delivering actionable insights on ground movement, vegetation management, and deforestation.LiveEO's innovative approach is redefining industry practices, improving operational efficiency, and safeguarding infrastructure safety and sustainability, setting new standards in asset management. | $26.8M / Series B / Jun 25, 2024 | |
|
OneTwenty
|
OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes. | Pre-Seed / Jan 19, 2024 | |
|
OneTwenty
|
OneTwenty is an early-stage health tech start-up that develops multiple Machine Learning based solutions for people with diabetes as well as Medtech companies for sensor optimization, biomarker prediction, glucoregulatory models, and iAGC (interoperable automated glycemic controller). Our solution demonstrates unprecedented precision in bloodglucose prediction 120 minutes in advance. OneTwenty revolutionizes the life of people with Type 1 diabetes. | Pre-Seed / Jan 19, 2024 | |
| See all 90 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does DvH Ventures invest in?
DvH Ventures invests primarily in Health Care, Software and Financial Services startups, most often at Seed and Series A stage. Most of the 90 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is DvH Ventures's check size?
DvH Ventures typically joins rounds of $1.2M–$7.7M at Seed and $3.8M–$31M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DvH Ventures participates in.
How do I contact DvH Ventures?
Public channels for DvH Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DvH Ventures?
The team at DvH Ventures includes Gabriel Grabner (Venture Partner), Peter Richarz (Founding Partner) and Caner Uslu (Investment Analyst), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
